Literature DB >> 18780781

A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells.

Emmanouil D Karagiannis1, Aleksander S Popel.   

Abstract

We introduce a systematic computational methodology based on bioinformatics that has enabled us to identify and classify >120 endogenous peptide inhibitors of endothelial cell proliferation and migration. These peptides are derived from members of the type IV collagen, thrombospondin, and CXC chemokine protein families, as well as somatotropin hormones, serpins, and various kringle-containing proteins. Their activity in suppressing the proliferation and migration of endothelial cells in vitro provides proof of principle for the validity of this computational method. Interestingly, some of the peptides are derived from proteins known to be proangiogenic. By performing receptor neutralization studies, we have identified receptors to which these peptides bind. On the basis of this receptor-binding information, we evaluated several examples of peptide-based combinatorial screening strategies. In some cases, this combinatorial screening identified strong synergism between peptides. The current work provides a guideline for a computational-based peptidomics approach for the discovery of endogenous bioactive peptides.

Mesh:

Substances:

Year:  2008        PMID: 18780781      PMCID: PMC2544530          DOI: 10.1073/pnas.0803241105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.

Authors:  R W Colman; B A Jameson; Y Lin; D Johnson; S A Mousa
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

2.  NC1 domain of human type VIII collagen (alpha 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis.

Authors:  R Xu; Z Y Yao; L Xin; Q Zhang; T P Li; R B Gan
Journal:  Biochem Biophys Res Commun       Date:  2001-11-23       Impact factor: 3.575

3.  Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin.

Authors:  Y Maeshima; M Manfredi; C Reimer; K A Holthaus; H Hopfer; B R Chandamuri; S Kharbanda; R Kalluri
Journal:  J Biol Chem       Date:  2001-02-07       Impact factor: 5.157

4.  Maspin is an angiogenesis inhibitor.

Authors:  M Zhang; O Volpert; Y H Shi; N Bouck
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

5.  Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

6.  Angiotensinogen and its cleaved derivatives inhibit angiogenesis.

Authors:  Jérôme Célérier; Amauri Cruz; Noël Lamandé; Jean-Marie Gasc; Pierre Corvol
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

7.  Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth.

Authors:  G D Kamphaus; P C Colorado; D J Panka; H Hopfer; R Ramchandran; A Torre; Y Maeshima; J W Mier; V P Sukhatme; R Kalluri
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

8.  Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan.

Authors:  Maurizio Mongiat; Shawn M Sweeney; James D San Antonio; Jian Fu; Renato V Iozzo
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

9.  The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells.

Authors:  G Spinetti; G Camarda; G Bernardini; S Romano Di Peppe; M C Capogrossi; M Napolitano
Journal:  Biochem Biophys Res Commun       Date:  2001-11-23       Impact factor: 3.575

10.  Structural elements of kallistatin required for inhibition of angiogenesis.

Authors:  Robert Q Miao; Vincent Chen; Lee Chao; Julie Chao
Journal:  Am J Physiol Cell Physiol       Date:  2003-06       Impact factor: 4.249

View more
  39 in total

1.  Structure-activity relationship study of collagen-derived anti-angiogenic biomimetic peptides.

Authors:  Elena V Rosca; Jacob E Koskimaki; Niranjan B Pandey; Amir P Tamiz; Aleksander S Popel
Journal:  Chem Biol Drug Des       Date:  2012-04-27       Impact factor: 2.817

2.  Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts.

Authors:  Jacob E Koskimaki; Emmanouil D Karagiannis; Elena V Rosca; Farhad Vesuna; Paul T Winnard; Venu Raman; Zaver M Bhujwalla; Aleksander S Popel
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

3.  Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.

Authors:  Raquel Lima E Silva; Yogita Kanan; Adam C Mirando; Jayoung Kim; Ron B Shmueli; Valeria E Lorenc; Seth D Fortmann; Jason Sciamanna; Niranjan B Pandey; Jordan J Green; Aleksander S Popel; Peter A Campochiaro
Journal:  Sci Transl Med       Date:  2017-01-18       Impact factor: 17.956

4.  Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells.

Authors:  Eric M Bressler; Jayoung Kim; Ron B Shmueli; Adam C Mirando; Hojjat Bazzazi; Esak Lee; Aleksander S Popel; Niranjan B Pandey; Jordan J Green
Journal:  J Biomed Mater Res A       Date:  2018-02-23       Impact factor: 4.396

5.  Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors.

Authors:  Jacob E Koskimaki; Esak Lee; William Chen; Corban G Rivera; Elena V Rosca; Niranjan B Pandey; Aleksander S Popel
Journal:  Angiogenesis       Date:  2012-09-29       Impact factor: 9.596

6.  Vasculature-specific MRI reveals differential anti-angiogenic effects of a biomimetic peptide in an orthotopic breast cancer model.

Authors:  Eugene Kim; Esak Lee; Charlesa Plummer; Stacy Gil; Aleksander S Popel; Arvind P Pathak
Journal:  Angiogenesis       Date:  2014-11-19       Impact factor: 9.596

7.  Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity.

Authors:  Corban G Rivera; Elena V Rosca; Niranjan B Pandey; Jacob E Koskimaki; Joel S Bader; Aleksander S Popel
Journal:  J Med Chem       Date:  2011-09-13       Impact factor: 7.446

8.  Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.

Authors:  Jayoung Kim; Raquel Lima E Silva; Ron B Shmueli; Adam C Mirando; Stephany Y Tzeng; Niranjan B Pandey; Elana Ben-Akiva; Aleksander S Popel; Peter A Campochiaro; Jordan J Green
Journal:  Acta Biomater       Date:  2019-07-30       Impact factor: 8.947

9.  Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model.

Authors:  Jacob E Koskimaki; Emmanouil D Karagiannis; Benjamin C Tang; Hans Hammers; D Neil Watkins; Roberto Pili; Aleksander S Popel
Journal:  BMC Cancer       Date:  2010-02-01       Impact factor: 4.430

10.  Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A.

Authors:  Esak Lee; Jacob E Koskimaki; Niranjan B Pandey; Aleksander S Popel
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.